...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Peripheral T-cell lymphoma in HIV-infected patients: A study of 17 cases in the combination antiretroviral therapy era
【24h】

Peripheral T-cell lymphoma in HIV-infected patients: A study of 17 cases in the combination antiretroviral therapy era

机译：HIV感染患者的外周T细胞淋巴瘤：抗逆转录病毒疗法联合时代的17例研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Most cases of human immunodeficiency virus (HIV)-associated non-Hodgkin Lymphoma (NHL) are of B-cell origin; T-cell NHLs are rarely reported. Within a single centre prospective cohort of 370 HIV-NHL, 17 (5%) were of T-cell origin (82% male; median age, 39 years). Median CD4+ cell count was 0·194 × 109/l and 41% had undetectable plasma HIV-RNA at lymphoma diagnosis. All patients received combination antiretroviral therapy during chemotherapy. All histological samples were centrally reviewed. The distribution of the histological subtypes differed from the general population with absence of angioimmunoblastic subtype. Lymphoma was disseminated in 14 patients, and seven patients had performance status 2. All patients received full-dose chemotherapy: eight standard and nine intensive regimens. Two patients who received intensive chemotherapy died during therapy. The complete remission rate was 53%; 62·5% with standard therapy and 44% with intensive therapy. After a median follow-up of 7·2 years, the median overall survival was 9·4 months. Most deaths (85%) occurred within the first year following diagnosis, as a consequence of lymphoma progression in 10/13 cases. In this rare but severe complication of HIV infection the use of intensive chemotherapy does not appear to be beneficial for response, with increased toxicity.
机译：大多数与人类免疫缺陷病毒（HIV）相关的非霍奇金淋巴瘤（NHL）病例都是B细胞起源的;很少报道T细胞NHL。在单个中心的370个HIV-NHL前瞻性队列中，有17个（5％）来自T细胞（男性82％;中位年龄39岁）。诊断淋巴瘤时，CD4 +细胞中位数为0·194×109 / l，41％的血浆HIV-RNA不可检测。所有患者在化疗期间均接受了抗逆转录病毒疗法的联合治疗。集中检查所有组织学样本。组织学亚型的分布不同于没有血管免疫母细胞亚型的一般人群。淋巴瘤在14例患者中传播，7例患者的表现状态> 2。所有患者均接受全剂量化疗：八种标准方案和九种强化方案。两名接受强化化疗的患者在治疗期间死亡。完全缓解率为53％;标准疗法为62·5％，强化疗法为44％。中位随访7·2年后，中位总生存期为9·4个月。大多数死亡（85％）发生在诊断后的第一年内，这是由于10/13例淋巴瘤进展所致。在这种罕见但严重的HIV感染并发症中，使用强力化疗似乎对缓解无益，毒性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号